Eugen Leo, MD, PhD, MBA, is a targeted therapy development specialist with board certifications in internal medicine, hematology and medical oncology. He has over 15 years of experience in phase I-III clinical development of targeted molecules (antibodies, antibody derivatives, kinase inhibitors, vaccines, and antisense molecules), and has an outstanding track record for successful drug development in oncology, hematology, rheumatology and related fields. He was instrumental in reaching proof-of-concept for the BiTE platform (blinatumomab; Science 321 (5891): 974ff) and in developing various other first-in-class molecules. He is the founder and owner of LEOconsulting, a prime biotech and pharmaceutical industry consulting service providing rational, rapid, intelligent and creative drug development since 2009. His academic credentials include an associate professorship at the University of Heidelberg, Department of Hematology & Medical Oncology.

Prior to starting his consultancy service, Dr. Leo served in various scientific and clinical development positions with growing responsibilities up to Vice President/Global Head Early Clinical Development at the biotech firm Micromet AG and at the pharmaceutical companies Johnson&Johnson Inc. and Merck-Serono GmbH. He has substantial translational research experience and, prior to his industry career, spent three years as research fellow at the Sanford-Burnham Institute, La Jolla, CA, USA, working on signal transduction in cancer. He studied Medicine at Freiburg, Münster and Heidelberg Universities in Germany and the University of Cincinnati in the US. He is ESMO-certified and obtained an MBA from Colorado State University.

A detailed CV is available upon request.

Qualifications and experience:

  • MD PhD MBA with board certification in Internal Medicine, Hematology and Medical Oncology
  • Profound, hands-on experience in antibody and antibody derivative, kinase inhibitor, vaccine and antisense molecule development (discovery to phase III)
  • Expertise in oncology, hematology, rheumatology and ophthalmology therapeutics with proven skills in compound development
  • 15+ years hands-on experience in targeted therapy development
  • 10+ years hands-on experience in industrial drug development
  • 7+ years of hands-on clinical oncology/cancer patient treatment and cancer research experience
  • Distinct first-in-class molecule experience (e.g. MABEL qualifiers)
  • Distinct biosimilar experience
  • Extensive agency interactions (FDA, EMA, PEI, BfArM)